Abstract:Background: Acute lung injury (ALI) is a severe inflammatory disorder associated with high morbidity and mortality rates. Various therapeutic strategies for ALI have been proposed over the last few decades; however, the treatment options remain limited. Mai-Luo-Ning injection (MLN), a traditional Chinese medical formulation, has been extensively used for the treatment of respiratory diseases. Nevertheless, the effects of MLN on ALI remain unclear. Purpose: This study aimed to investigate the protective and therapeutic effects of MLN on lipopolysaccharide-induced ALI mouse models and RAW 264.7 cells, and further explore the underlying mechanism of these effects. Methods: The therapeutic activity of MLN was evaluated using an in vivo ALI model and an in vitro model of RAW 264.7 macrophages. UHPLC-ESI-Q-TOF-MS/MS was used to investigate the chemical constituents of the MLN. The material basis and potential protective mechanism of MLN were analyzed using network pharmacology. The roles of MLN in inhibiting the Toll-like receptor 4 (TLR4)/ nuclear factor kappa B (NF-κB) signalling pathway were investigated via western blotting, real-time polymerase chain reaction, enzyme-linked immunosorbent assay, and immunofluorescence staining. Results: In vivo experiments demonstrated that MLN ameliorated LPS-induced histological changes in lung tissues and reduced lung wet/dry weight ratio, total protein concentration in the bronchoalveolar lavage fluid and myeloperoxidase activity. Furthermore, MLN downregulated the in vivo and in vitro expression of pro-inflammatory cytokines such as tumour necrosis factor-alpha, interleukin-6, and interleukin-1β. Network pharmacology analysis revealed that MLN could act synergistically through multiple targets and pathways and exert a protective effect, possibly through inhibiting TLR4/ NF-κB signalling pathways. Western blotting and immunofluorescence experiments further confirmed that MLN could regulate the expression of TLR4, MyD88, phospho-IκB-α, and phospho-NF-κB p65 in the TLR4/NF-κB signalling pathway and decrease the translocation of phospho-NF-κB p65 into the nucleus. Conclusion: This study suggests that MLN has a potential protective effect against LPS-induced ALI, which might be associated with the inhibition of the TLR4/NF-κB signalling pathway. Therefore, MLN is worthy of further investigation as a potential candidate for the treatment of ALI in the future.

The Novel N-methyl-d-aspartate Receptor Antagonist MN-08 Ameliorates Lipopolysaccharide-Induced Acute Lung Injury in Mice.

[Protective Effect Against Monoammonium Glycyrrhizinate on Lipopolysaccharide-Induced Acute Lung Injury in Mice].

Monoammonium Glycyrrhizinate Inhibited The Inflammation Of Lps-Induced Acute Lung Injury In Mice

Plantamajoside Ameliorates Lipopolysaccharide-Induced Acute Lung Injury Via Suppressing NF-κB and MAPK Activation.

Standardized Myrtol Attenuates Lipopolysaccharide Induced Acute Lung Injury in Mice

MNK as a potential pharmacological target for suppressing LPS-induced acute lung injury in mice

[Protective Effect of NMDA Receptor Antagonist Memantine on Acute Lung Injury in Mice].

Memantine Nitrate MN-08 Suppresses NLRP3 Inflammasome Activation to Protect Against Sepsis-Induced Acute Lung Injury in Mice

JNK‑IN‑8 Treatment Alleviates Lipopolysaccharide‑induced Acute Lung Injury Via Suppression of Inflammation and Oxidative Stress Regulated by JNK/NF‑κB Signaling.

Effects of ambroxol on nuclear factor-kappa B signaling transduction in lipopolysaccaride-induced acute lung injury in rats

Magnoflorine Ameliorates Lipopolysaccharide-Induced Acute Lung Injury Via Suppressing NF-κB and MAPK Activation

Andrographolide Sulfonate Ameliorates Lipopolysaccharide-Induced Acute Lung Injury in Mice by Down-Regulating MAPK and NF-κB Pathways.

Amygdalin Alleviates LPS-induced Acute Lung Injury in Mice by Targeting CD5L/iNOS Pathway

SB203580 Protects Against Inflammatory Response and Lung Injury in a Mouse Model of Lipopolysaccharide‑induced Acute Lung Injury.

Andrographolide Derivative AL-1 Ameliorates LPS-induced Acute Lung Injury by Inhibiting NLRP3 Inflammasome and Lung Permeability

A Microsatellite DNA-derived Oligodeoxynucleotide Attenuates Lipopolysaccharide-Induced Acute Lung Injury in Mice by Inhibiting the HMGB1-TLR4-NF-κB Signaling Pathway

Modified Xiaoqinglong decoction alleviates lipopolysaccharide‐induced acute lung injury in mice by regulating arachidonic acid metabolism and exerting anti‐apoptotic and anti‐inflammatory effects

Protective Effects of Danmu Extract Syrup on Acute Lung Injury Induced by Lipopolysaccharide in Mice through Endothelial Barrier Repair

The protective effects of Mai-Luo-Ning injection against LPS-induced acute lung injury via the TLR4/NF-κB signalling pathway

Targeting the PI3K/AKT Signaling Pathway with PNU120596 Protects Against LPS-induced Acute Lung Injury

Aspirin-triggered Lipoxin A4 Attenuates Lipopolysaccharide-Induced Acute Lung Injury by Inhibiting Activation of Mitogen-Activated Protein Kinases and NF-κB in Mice.